Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500)
Stephen H. Petersdorf(Fred Hutch Cancer Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Cheryl L. Willman(Mayo Clinic), Cathryn Rankin(Cleveland Clinic), Howard R. Terebelo(Michigan Cancer Research Consortium), David R. Head(University of Southern California), Stanley P. Balcerzak(University of Oklahoma Health Sciences Center), Shaker R. Dakhil(Cancer Center of Kansas), Anand B. Karnad(The University of Texas at San Antonio Health Science Center)
Cited by 29
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k